PATH vs RNA · P/E 19, rev $1.61B vs rev $10.9M
Uipath Inc (PATH) versus Atrium Therapeutics, Inc. Common Stock (RNA) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported RNA revenue for 2024-12-31 was $10.9M. Net income was -$322.3M. Revenue was up 14.0% from 2023-12-31 to 2024-12-31. RNA currently screens at market cap $217.5M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. RNA currently screens at market cap $217.5M.
Not investment advice. Open the PATH and RNA stock pages for the full models.
Not investment advice.